ORCID
- Hanemann, Oliver: 0000-0002-1951-1025
Abstract
Abstract Background Variability in standard-of-care classifications precludes accurate predictions of early tumor recurrence for individual patients with meningioma, limiting the appropriate selection of patients who would benefit from adjuvant radiotherapy to delay recurrence. We aimed to develop an individualized prediction model of early recurrence risk combining clinical and molecular factors in meningioma. Methods DNA methylation profiles of clinically annotated tumor samples across multiple institutions were used to develop a methylome model of 5-year recurrence-free survival (RFS). Subsequently, a 5-year meningioma recurrence score was generated using a nomogram that integrated the methylome model with established prognostic clinical factors. Performance of both models was evaluated and compared with standard-of-care models using multiple independent cohorts. Results The methylome-based predictor of 5-year RFS performed favorably compared with a grade-based predictor when tested using the 3 validation cohorts (ΔAUC = 0.10, 95% CI: 0.03–0.018) and was independently associated with RFS after adjusting for histopathologic grade, extent of resection, and burden of copy number alterations (hazard ratio 3.6, 95% CI: 1.8–7.2, P < 0.001). A nomogram combining the methylome predictor with clinical factors demonstrated greater discrimination than a nomogram using clinical factors alone in 2 independent validation cohorts (ΔAUC = 0.25, 95% CI: 0.22–0.27) and resulted in 2 groups with distinct recurrence patterns (hazard ratio 7.7, 95% CI: 5.3–11.1, P < 0.001) with clinical implications. Conclusions The models developed and validated in this study provide important prognostic information not captured by previously established clinical and molecular factors which could be used to individualize decisions regarding postoperative therapeutic interventions, in particular whether to treat patients with adjuvant radiotherapy versus observation alone.
DOI
10.1093/neuonc/noz061
Publication Date
2019-07-01
Publication Title
Neuro-Oncology
Volume
21
Issue
7
ISSN
1522-8517
Embargo Period
2022-03-05
Organisational Unit
Peninsula Medical School
First Page
901
Last Page
910
Recommended Citation
Nassiri, F., Mamatjan, Y., Suppiah, S., Badhiwala, J., Mansouri, S., Karimi, S., Saarela, O., Poisson, L., Gepfner-Tuma, I., Schittenhelm, J., Ng, H., Noushmehr, H., Harter, P., Baumgarten, P., Weller, M., Preusser, M., Herold-Mende, C., Tatagiba, M., Tabatabai, G., Sahm, F., von, D., Aldape, K., Au, K., Barnhartz-Sloan, J., Bi, W., Brastianos, P., Butowski, N., Carlotti, C., Cusimano, M., Dimeco, F., Drummond, K., Dunn, I., Galanis, E., Giannini, C., Goldbrunner, R., Griffith, B., Hashizume, R., Hanemann, C., Herold-Mende, C., Horbinski, C., & Huang, R. (2019) 'DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management', Neuro-Oncology, 21(7), pp. 901-910. Available at: https://doi.org/10.1093/neuonc/noz061
